Updates

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Dr Jon E. Grant talks about the genetics, neurobiology, and cognitive processes of body-focused repetitive behaviors, which include trichotillomania, skin picking, and other behaviors.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.